Acute on Chronic Liver Failure Market Size in the 7MM is expected to grow at a significant CAGR by 2034, estimates DelveInsight

DelveInsight's "Acute on Chronic Liver Failure Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Acute on Chronic Liver Failure, historical and forecasted epidemiology as well as the Acute on Chronic Liver Failure market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover Key Insights into the Acute on Chronic Liver Failure Market with DelveInsight's In-Depth Report @ https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-market [https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Acute on Chronic Liver Failure Market Research Report

* In December 2025, Beijing Continent Pharmaceutical Co, Ltd. conducted a study was randomized, double-blind, placebo-controlled. The study was divided into a screening period (14 days), treatment period (28 days), and follow-up period (90 days).
* In December 2025, Hexaell Biotech Co. Ltd announced a phase 1/2 clinical study conducted in China to evaluate the efficacy, safety and tolerability of hiHep cell-based bio-artificial liver support system (HepaCure) plus DPMAS versus DPMAS alone in Chinese subjects with acute-on-chronic liver failure.
* According to DelveInsight's epidemiology model, there were approximately 61,543 total cases of ACLF in the 7MM in 2023. These cases are expected to increase during the forecast period (2024-2034), due to the increasing prevalence of chronic liver diseases.
* In 2023, the US accounted for approximately 13,175 total cases of ACLF which is expected to increase by 2034.
* Among the EU4 and the UK, Germany accounted for approximately 16,896 total cases of ACLF in 2023, followed by the UK with nearly 12,321 cases. On the other hand, Italy accounted for the least with approximately 1,728 cases.
* Japan accounted for approximately 3,654 total cases of ACLF in 2023 which is expected to change by 2034.
* Among the total cases of ACLF by grade, there were approximately 6,379 cases for Grade 1, 5,039 cases for Grade 2, and nearly 1,757 cases for Grade 3 in the US in 2023.
* In 2023, among the organ failures associated with ACLF in EU4 and the UK, there were approximately 20,875 cases of liver failure, 17,542 cases of kidney failure, 10,164 cases of cerebral failure, 11,076 cases of coagulation, 6,483 cases of circulation, and 3,268 cases of lungs failure.
* Among the potential precipitating events of ACLF in Japan, there were nearly 529 cases of bacterial infection, 312 cases of gastrointestinal hemorrhage, and 1,096 cases of alcoholism one year prior to the cirrhosis index date, 1,644 cases of infection or GIB or alcohol and 72 other cases in 2023. These cases are expected to change during the forecast period.
* The leading Acute on Chronic Liver Failure Companies such as Grifols Therapeutics, Promethera Biosciences, GENFIT, Akaza Bioscience, RHEACELL, Versantis, Martin Pharmaceuticals, Cipla , and others.
* Promising Acute on Chronic Liver failure Therapies such as HepaStem, hUC-MSC, F573 for injection and others.

Discover which therapies are expected to grab the Acute on Chronic Liver Failure market share @ Acute on Chronic Liver Failure Treatment Market [https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=yprhttps://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-market]

Acute on Chronic Liver Failure Epidemiology Segmentation in the 7MM

* Total Cases of ACLF
* Total Cases of ACLF by Grades
* Organ Failures Associated with ACLF
* Potential Precipitating Events of ACLF

Download the report to understand which factors are driving Acute on Chronic Liver Failure epidemiology trends @ Acute on Chronic Liver Failure Prevalence [https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=yprhttps://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-market]

Acute on Chronic Liver Failure Emerging Drugs

* Albumin 5% (PE-A 5%): Grifols Therapeutics

Albumin 5% (PE-A 5%) is an investigational therapy currently being evaluated in a Phase III international study, the APACHE trial. This study focuses on the use of therapeutic plasma exchange (TPE) with albumin replacement to eliminate both endogenous and exogenous toxic substances in patients suffering from ACLF, to prolong patient survival. Concurrently, Grifols is conducting translational research to complement this trial, offering crucial insights into the mechanisms underlying systemic inflammation, organ failure, and ACLF in cirrhosis.

* VS-01: GENFIT (Versantis)

VS-01-ACLF is an innovative investigational drug utilizing a proprietary scavenging liposomal technology. It is administered directly into the peritoneal (abdominal) cavity following the drainage of ascites, a common complication in patients with ACLF. VS-01 has received Orphan Drug Designation (ODD) for ACLF from the US FDA. VS-01 is currently being evaluated in the international UNVEIL-IT Phase II proof-of-concept study. This study aims to assess the efficacy, safety, and tolerability of VS-01 in addition to standard of care (SOC) compared to SOC alone in adult patients with ACLF grades 1 and 2 and ascites.

Acute on Chronic Liver Failure Drugs Market

Albumin 5% also known as PE-A 5% (Grifols Therapeutics), is a sterile liquid albumin preparation derived from large pools of human plasma and administered intravenously to increase plasma volume or albumin levels in the blood. It may also have immune-modulatory effects in decompensated cirrhosis by binding various pathogen-associated molecular patterns, DAMPs, and inflammatory mediators, preventing their interaction with receptors on endothelial and immune cells. This suggests it could be an effective modulator of the innate immune system for managing ACLF, and Grifols Therapeutics is focusing on this potential.

Acute on Chronic Liver Failure Treatment Market Landscape

Management focuses on early identification, treating precipitating factors (such as bacterial infections, Hepatitis B Virus, and alcoholic hepatitis), and providing supportive care for organ failures. Prognosis assessment and determining the need for liver support, including potential liver transplantation (LT), are also essential. LT remains the definitive treatment for ACLF, but it is often limited by donor shortages and frequent contraindications in these patients.

Get In-Depth Knowledge on Acute on Chronic Liver Failure Market Trends and Forecasts with DelveInsight @ Acute on Chronic Liver Failure Market Drivers and Barriers [https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=yprhttps://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-market]

Acute on Chronic Liver Failure Companies

Grifols Therapeutics, Promethera Biosciences, GENFIT, Akaza Bioscience, RHEACELL, Versantis, Martin Pharmaceuticals, Cipla , and others.

Acute on Chronic Liver Failure Therapeutics Market

Therapeutic options for ACLF focus on preventing the progression of multiorgan dysfunction, such as renal failure, sepsis (including aspiration pneumonia), metabolic disorders, cerebral edema, encephalopathy, and coagulopathy. The revenue from pharmacological therapies, however, is not as substantial as that from surgical or procedural interventions, leaving a significant gap in the ACLF market. Major pharmaceutical companies have recognized this opportunity and are actively exploring this area for long-term growth. Due to the multifactorial nature of ACLF, a single therapeutic agent is unlikely to be effective, prompting companies to focus on multifaceted treatment approaches. Research has advanced considerably over the past decade, aided by extensive published data globally. The anticipated launch of new therapies is expected to drive ACLF market growth.

Scope of the Acute on Chronic Liver Failure Market Research Report

* Coverage- 7MM
* Study Period- 2020-2034
* Acute on Chronic Liver Failure Companies- Grifols Therapeutics, Promethera Biosciences, GENFIT, Akaza Bioscience, RHEACELL, Versantis, Martin Pharmaceuticals, Cipla , and others.
* Acute on Chronic Liver Failure Pipeline Therapies- HepaStem, hUC-MSC, F573 for injection and others.
* Acute on Chronic Liver Failure Market Dynamics: Acute on Chronic Liver Failure Market Drivers and Barriers
* Acute on Chronic Liver Failure Market Access and Reimbursement, Unmet Needs, Analyst Views

Discover more about Acute on Chronic Liver Failure Drugs in development @ Acute on Chronic Liver Failure Ongoing Clinical Trials [https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=yprhttps://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-market]

Table of Content

1. Key Insights

2. Acute on Chronic Liver Failure Executive Summary

3. Competitive Intelligence Analysis for Acute on Chronic Liver Failure

4. Acute on Chronic Liver Failure: Market Overview at a Glance

5. Acute on Chronic Liver Failure: Disease Background and Overview

6. Patient Journey

7. Acute on Chronic Liver Failure Epidemiology and Patient Population

8. Acute on Chronic Liver Failure Treatment Algorithm, Current Treatment, and Medical Practices

9. Acute on Chronic Liver Failure Unmet Needs

10. Key Endpoints of Acute on Chronic Liver Failure Treatment

11. Acute on Chronic Liver Failure Marketed Products

12. Acute on Chronic Liver Failure Emerging Therapies

13. Acute on Chronic Liver Failure: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Acute on Chronic Liver Failure Market Access and Reimbursement Overview

17. Acute on Chronic Liver Failure KOL Views

18. Acute on Chronic Liver Failure Market Drivers

19. Acute on Chronic Liver Failure Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=acute-on-chronic-liver-failure-market-size-in-the-7mm-is-expected-to-grow-at-a-significant-cagr-by-2034-estimates-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/acute-on-chronic-liver-failure-aclf-market

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.